Data analysis highlights protective effect of Edoxaban against stroke

Edoxaban (Lixiana) provides comparable efficacy and greater safety compared to warfarin, sub-analysis data presented at the European Society of Cardiology Congress in Barcelona, Spain, has revealed. The findigs apply to non-valvular atrial fibrillation (NVAF) patients with different stroke risk scores, and are based on a sub-analysis of the Effective aNticoaGulation with factor XA next GEneration in Atrial Fibrillation (ENGAGE AF-TIMI 48) clinical study. The resultsprovide more specific insights into the use of oral, once-daily direct factor Xa-inhibitor edoxaban compared to warfarin in NVAF patients grouped by stroke risk (as measured by CHA2DS2-VASc score). The ENGAGE AF-TIMI 48 study has previously